tirzepatide and surgery (Mounjaro) In Sherman Oaks Zepbound No Longer in Shortage:

FDA withdrew its draft guidance on help-seeking advertisements in 2015.[18] FDA issued a subsequent, final guidance that states that compounded drug products intended for use in humans must not have labeling, advertising, and promotion that is false or misleading, and, as noted above, the Advertisement is misleading with respect to side effects, contraindications, and effectiveness.[19] FDAs guidance also states that if an individual or firm compounds a drug product that does not meet the conditions of the FDCA, including those regarding labeling, advertising, and promotion, then the individual or firm that compounds the drug product may also be subject to a warning letter, seizure of product, injunction, and/or criminal prosecution for violations of the FDCA.[20] Fourth, the APC has argued that compounded medications have different rules for marketing and advertising and that the Federal Trade Commission (FTC) regulates advertising for non-FDA approved products, including compounded drugs

Key takeaways What is Mounjaro

For diabetic patients, medication reduction or elimination may be possible with physician guidance

This new class of antiobesity medications (AOMs) offers substantial clinical benefits, such as sizable weight loss and reductions in obesity-related comorbidities